TRANSCRIPT

Q2 2023 — Earnings call remarks

Q2 2023PDF · 10 pages151 KB
Earnings Conference Call
Second Quarter 2023 Remarks
July 14, 2023
Moderator:
Good morning, and welcome to the UnitedHealth Group Second Quarter 2023 Earnings
Conference Call. A question and answer session will follow UnitedHealth Group’s prepared
remarks. As a reminder, this call is being recorded.
Here is some important introductory information. This call contains “forward-looking” statements
under U.S. federal securities laws. These statements are subject to risks and uncertainties that
could cause actual results to differ materially from historical experience or present expectations.
A description of some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements included in our
current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-GAAP to GAAP
amounts is available on the “Financial & Earnings Reports” section of the Company’s Investor
Relations page at www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued this morning
and in our Form 8-K dated July 14, 2023, which may be accessed from the Investor Relations
page of the Company’s website. I will now turn the conference over to the chief executive
officer of UnitedHealth Group, Andrew Witty.
Andrew Witty
Thank you. Good morning and thank you all for joining us.
As we discussed a number of weeks ago, during the quarter, we saw a somewhat
higher than usual range of movement in certain areas of care activity. As you would
expect, this inevitably impacted some elements of our business, but we overcame these
dynamics with strength in other areas.

-- 1 of 10 --

2
Our second quarter performance reflects the capabilities, agility and dedication of our
people as they responded to the changes. As a team, we are confident in our ability to
robustly grow in this fluid health care environment.
Indeed, as I hope you saw in our release today, revenue growth in the quarter was
strong and well balanced across our enterprise, increasing by more than $12 billion to
nearly $93 billion.
Let me provide a few highlights of our growth. First: the number of patients served by
Optum Health under fully accountable, value-based care arrangements grew by more
than 900,000 over this time last year. Among the new patients we welcomed, a
significant number have complex needs.
These people have serious health challenges, limited economic resources and often live
in communities where it can be difficult to access high-quality care. Our ability to
support their needs is distinctive and a direct result of the investments we have made to
provide coordinated and comprehensive medical, pharmacy and behavioral care —
foundational capabilities that will help the patients we serve live healthier lives and drive
growth far into the future.
Optum Rx and Optum Insight revenue grew double digits on expanded capabilities and
products that are generating new sales and opportunities.
UnitedHealthcare’s growth was strong and diversified, as well. Today we are serving
nearly 1.6 million more people in our commercial and public sector program offerings
than we did last year.
This durable growth, driven by our colleagues’ relentless focus on quality and execution,
enabled us to achieve second quarter adjusted earnings per share of $6.14 and to
strengthen our full year outlook to between $24.70 to $25.00 per share.

-- 2 of 10 --

3
We know there is great interest in understanding the recent care activity I just
mentioned, so I’ll give you an overview of how we are seeing care patterns progress
and how we are responding.
I do want to underscore the most critical point first: making high-quality care more
affordable and accessible is at the core of our mission. Having more people obtaining
the care they need is a positive trend for individuals, and our health system and society.
As we discussed several weeks ago, during the second quarter we observed increased
care patterns, notably in outpatient surgeries for seniors and especially with certain
orthopedic procedures which may have been postponed. John will provide some
additional detail on this later.
As we look to 2024, we have developed compelling Medicare Advantage offerings. Our
teams were of course thoughtful both in our response to the CMS rate notice and in
incorporating these care activity trends into our June benefit filings.
Even in this challenging funding environment, we continued to prioritize the stability and
affordability our members have come to rely on from UnitedHealthcare. We are
confident that next year we will once again grow at a pace exceeding that of the broader
market.
While of a much lesser impact than senior outpatient care, we also are seeing increased
care activity in behavioral. Over the past few years, behavioral care patterns have been
accelerating as people increasingly feel comfortable seeking services. Just since last
year the percentage of people who are accessing behavioral care has increased by
double digits. From our perspective, it is an encouraging sign that more people are
seeking help, yet the ongoing shortage of qualified care providers has caused
significant access challenges. To address the issue, Optum Health has expanded its
network by tens of thousands of care professionals this year, and we are developing our
benefit offerings assuming demand for behavioral care services will continue to rise.

-- 3 of 10 --

4
Optum Health’s value-based care models are continuing to deliver especially strong and
measurable results for people, today serving more than 4 million patients and dozens of
payers.
Optum Health and the patients and payers it serves share a common desire to seek
improved health outcomes and experiences … while ultimately lowering the costs of
care … and we are pleased to see more evidence supporting the efficacy of value-
based care.
Last month researchers at Yale Medicine, working in collaboration with Optum,
published a peer-reviewed study about in-home visits, an important element in our
value-based care approach. The study found patients who received our in-home,
preventive wellness assessments — compared with those who hadn’t — made fewer
emergency department visits and spent fewer nights in hospitals across four common
conditions — depression, hypertension, coronary artery disease and Type 2 diabetes.
They also experienced reduced wait times for follow-up primary care.
Yale Medicine’s research follows another peer-reviewed study published in JAMA in
December, which found Medicare Advantage patients in Optum’s fully accountable care
model showed significantly better health outcomes compared to people in Medicare fee-
for-service. Optum Health patients fared better on each of eight key metrics, including
hospital readmissions and emergency department visits.
We see these results as compelling validation of the value-based care approach and
signal more strongly its promise and potential as we expand these care models to many
millions more patients in the years ahead.
I’ll now turn it over to UnitedHealth Group President and Chief Operating Officer
Dirk McMahon to elaborate on how we are focusing on affordability, transparency and
simplicity for the people we serve.

-- 4 of 10 --

5
Dirk?
Dirk McMahon
Thanks, Andrew.
Making high-quality care more affordable and more accessible is what we do. So it is
really great to see people getting the care they need — especially as our teams are
working to build more capacity in our benefit networks and care delivery resources to
accommodate consumers’ evolving needs.
Affordability is vital. For far too many people, cost remains the most significant barrier to
high-quality care.
We are leaning in hard on behalf of consumers, employers and health plans to lower
out-of-pocket costs and drive greater affordability throughout the system.
As you heard from Andrew, recently we’ve seen an uptick in outpatient surgeries.
Finding the most appropriate site of service is crucial because the cost of those
procedures can differ dramatically depending upon where they are performed.
Overall, evidence shows that comparable procedures performed in ambulatory surgery
centers cost about half as much as traditional settings, with comparable outcomes. For
consumers, that translates into many hundreds of dollars in out-of-pocket cost savings
for just a single procedure. And the patient satisfaction levels at our centers are among
the highest in health care, with NPS approaching 90.
Also high on our affordability agenda is continuing to lower the cost of prescription
drugs.

-- 5 of 10 --

6
Our customers — including employers, unions, health plans and governments — count
on us to help them access the most effective medicines at the lowest possible cost. In
fact, pharmacy benefit managers like ours are the only link in the drug supply chain
whose main purpose is to improve affordability for everyone.
We go further by recommending benefit designs and providing tools to help consumers
navigate their options and find the best value for their prescriptions. A recently launched
feature called Price Edge, which provides the lowest cost option for a patient’s
medication, already has delivered millions of dollars in consumer out-of-pocket savings.
Specialty drug costs continue to be a focus of every customer Optum Rx works with.
Our differentiated approach to specialty is designed to serve the unique needs of
patients, payers, providers and pharma partners, and has allowed us to greatly expand
our access to limited distribution drugs. We work to tailor our programs with
individualized single-point-of-contact care for rare disease and clinical excellence
programs for conditions such as MS, autoimmune diseases and cancer. Clients working
with Optum Rx who implement all our specialty medication management programs can
save up to 20% on their specialty drug costs.
Closely related to specialty, biosimilars are another area where we are helping drive
affordability and consumer choice. Earlier this year, we began offering Amjevita — a
biosimilar to Humira — at parity, ensuring patients and their doctors have more options
to choose from when deciding on a course of care. Recently, Optum Rx and
UnitedHealthcare announced the addition of two new Humira biosimilars, Cyltezo and
Hyrimoz, to our standard prescription drug lists, also at parity. This increased
competition for the innovator drug will result in double digit savings for our customers.
You might also recall that a year ago we announced our initiative to offer lifesaving
drugs at no cost to our customers. This benefit is available to everyone in
UnitedHealthcare’s group fully insured commercial plans, and has been adopted by

-- 6 of 10 --

7
more than 500 of our self-funded customers, increasing adherence and saving people
millions of dollars.
Finally, another important customer innovation that is making the health system simpler
is Optum Financial’s integrated card, which enables seamless access to benefits,
programs and rewards for more than 13 million consumers who have been issued the
card since we broadly rolled it out at the start of the year. Adoption and satisfaction
levels have been very strong — making it much simpler for seniors to navigate the
system and understand their benefits … and creating a more satisfying consumer
experience.
These and many other results are validating our strategic approach to health care. I
know from my many meetings with customers that these affordability, transparency and
simplicity initiatives are resonating. They are a key reason for our continued growth in a
highly competitive environment, and for our confidence in maintaining our momentum
as we look ahead.
With that, let me hand it over to Chief Financial Officer John Rex.
John Rex
Thank you, Dirk.
Adaptability and delivering greater value for the people we serve continue as
foundational elements of our enterprise. These last few months are a good example …
identifying evolving market trends … moving quickly to help people get the care they
need … incorporating our broad and multifaceted insights into planning … and
importantly … delivering on our commitments to you, our shareholders.
These traits underpin our confidence not only in achieving our goals for ’23, but also as
we look toward ’24 and beyond.

-- 7 of 10 --

8
Before reviewing our business results, let me elaborate on the care patterns Andrew
described earlier.
To illustrate: in the second quarter outpatient care activity among seniors was a few
hundred basis points above our expectations. As we’ve highlighted, specific orthopedic
and cardiac procedures had increases far above that level of variation.
And as we developed and filed our 2024 Medicare Advantage offerings, we assumed
that these levels of heightened care activity will persist throughout next year.
Overall care activity among our Medicaid and commercial populations is consistent with
our expectations.
As always, we continue to intensely analyze trends that may indicate more severe
disease progression, which could point to rising acuity … for example, in areas such as
cancer or cardiovascular disease. We see no such evidence, while continuing to
monitor closely.
With that, let’s turn to our second quarter results.
Revenue of $92.9 billion grew by nearly $12.6 billion or 16% over the prior year, with
double-digit growth at both Optum and UnitedHealthcare.
Optum Health revenues grew by 36% to $23.9 billion, driven by an increase in the
number of patients served, a growing mix of patients with more complex needs, and the
expanding scope of care services we can offer. Operating margins reflect the higher
care activity patterns we have discussed, with seniors comprising a significant majority
of value-based patients served.
Optum Rx revenues grew by 15%, surpassing $28 billion, driven by continued new
customer wins and strong double-digit growth across our specialty, infusion and

-- 8 of 10 --

9
community pharmacies. Script growth of nearly 7% reflects continued demand for our
affordable solutions that give customers choice and simplify the pharmacy experience,
such as biosimilar access and digital pharmacy tools. Partway into the ‘24 selling
season, this momentum continues, with strong client additions.
Optum Insight revenues grew 42% to nearly $4.7 billion. The revenue backlog reached
over $31 billion, an increase of $8 billion over last year, in part due to the addition of
Change Healthcare. The integration and investment activities discussed on previous
calls have gone well and are setting the stage for the next phase of growth for Optum
Insight.
Turning to UnitedHealthcare:
Our commercial business added nearly 500,000 people in the first half and continues its
growth, with the ‘24 selling season indications tracking favorably. Within our public
sector programs, we continue to expect growth of over 900,000 Medicare Advantage
members this year. And our Medicaid performance remains strong as we continue to
support states as they initiate redeterminations. Comprehensive outreach efforts to help
individuals retain coverage are underway, though it is still early, as most states began
this work only recently.
Our capital capacities are strong. Adjusted cash flows from operations were at
$10.4 billion or nearly two times net income in the second quarter and $15.6 billion or
nearly 1.4 times net income in the first half.
In the first six months of this year, we returned $8.3 billion to shareholders through
dividends and share repurchases. And in June, our Board of Directors increased the
dividend by 14%.
As Andrew mentioned, based upon our growth outlook and the trends discussed, today
we were able to strengthen and narrow our full year ‘23 adjusted earnings outlook to a

-- 9 of 10 --

10
range of $24.70 to $25.00 per share. Within this, we expect a relatively balanced pacing
in the second half.
Now I’ll turn it back to Andrew.
Andrew Witty
John, thank you.
Overall, for UnitedHealth Group, looking to the second half of the year … and into 2024
and beyond … we are confident that we are capturing the current landscape in our
planning decisions … which in turn gives us confidence in our ability to sustain the
growth momentum shown in our first half and continue to demonstrate the adaptability,
performance and mission-driven purpose of this enterprise … especially in evolving
environments.

-- 10 of 10 --